anti-PD-L1/anti-TIGIT bispecific antibody PM1022

{
  "id": "MLC-T-ONC-011020",
  "term": "anti-PD-L1/anti-TIGIT bispecific antibody PM1022",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant humanized bispecific antibody directed against both the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-TIGIT/anti-PD-L1 bispecific antibody PM1022 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways. Inhibition of TIGIT, which is expressed on various immune cells and particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. Inhibition of PD-L1 prevents its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion. PD-L1 binding to PD-1 on activated T cells inhibits the expansion and survival of CD8-positive T cells, suppresses the immune system and results in immune evasion.",
  "synonyms": [
    "anti-PD-L1/TIGIT bispecific antibody PM1022",
    "anti-TIGIT/anti-PD-L1 bispecific antibody PM1022",
    "TIGIT x PD-L1 bispecific antibody PM1022",
    "anti-TIGIT/PD-L1 bispecific antibody PM1022",
    "PD-L1 x TIGIT bispecific antibody PM 1022"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-l1-anti-tigit-bispecific-antibody-pm1022/"
}